Psychiatric disorders are prevalent and disabling. Despite investment over the past 2 decades, few new treatments emerged, and drug trials repeatedly ended in disappointment.1 In 2014, the National Institute of Mental Health (NIMH) announced a new vision for treatment development, requiring investigators to establish mechanistic targets of interventions before testing efficacy in clinical trials.1 Proponents maintain this approach focuses investment towards the most promising treatments and ensures even failed trials improve mechanistic understanding. Critics argue it impedes studying interventions that could help patients today.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kayser RR, Arbuckle M, Simpson HB. Pipeline in Jeopardy—Challenges in Developing Patient-Oriented Interventions Researchers in Psychiatry and Opportunities for Action. JAMA Psychiatry. 2022;79(2):95–96. doi:10.1001/jamapsychiatry.2021.3262
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.